Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 301 - 350 out of 122,159

Document Document Title
WO/2017/049252A1
The present invention generally provides vectors, compositions, and methods of using the same for treating neurological disorders, including managing pain. The compositions and methods include the use of G protein-coupled receptors and l...  
WO/2017/046117A1
Compounds of formula (I) (I) and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined in the specification, are useful in treating conditions or disorders prevented by or ameliorated by positive allosteric modu...  
WO/2017/048808A1
The present disclosure provides variant light-responsive polypeptides, and nucleic acids comprising nucleotide sequences encoding the light-responsive polypeptides. The present disclosure provides methods, devices, and systems for contro...  
WO/2017/046794A1
Provided herein piperazine and piperidine derivatives, their synthesis and use thereof in inhibiting VDAC oligomerization, apoptosis and mitochondria dysfunction. Also provided methods of treatment of diseases associated with said proces...  
WO/2017/046737A1
The invention is directed to substituted pyrrolidinone and imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, R6, R7, X and Y are as defined herein. T...  
WO/2017/049192A1
The disclosure relates to methods and compositions for reactivating a silenced FMR1 gene. In some aspects, methods described by the disclosure are useful for treating a FMR1- inactivation-associated disorder (e.g., fragile X syndrome).  
WO/2017/047776A1
Provided is a blood tryptophan concentration elevation inhibitor. The blood tryptophan concentration elevation inhibitor has, as an effective component thereof, lactic acid bacterium of the genus Lactobacillus, a processed product thereo...  
WO/2017/046675A1
The present invention provides novel imidazo[4,5-c]quinoline and imidazo[4,5-c][1,5]naphthyridine derivatives of Formula (I), and the pharmaceutically acceptable salts thereof wherein R1, R1a, R1b, R2, R4, R5, R6, X and Z are as defined ...  
WO/2017/046739A1
The invention is directed to substituted imidazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I (I) wherein R1, R2, R3, R4, R5, R6, R7, X, Y1, Y2 and Z are defined herein. The compounds o...  
WO/2017/046738A1
The invention is directed to substituted triazolidinone derivatives. Specifically, the invention is directed to compounds according to Formula I: (I) wherein R1, R2, R3, R4, R5, X, Y, Y1, and Z are as defined herein. The compounds of the...  
WO/2017/045599A1
Provided are a cyclohexane derivative as shown by formula IB or a stereoisomer or a salt thereof, and the preparation and use thereof. The cyclohexane derivative has a high affinity for D3 receptors and 5-hydroxytryptamine, has a lower a...  
WO/2017/045053A1
The present invention describes an oral pharmaceutical composition containing cannabinoid(s), an oily liquid solvent and a co-solvent, and a method for preparing and using same for the treatment of neurological disorders, especially refr...  
WO/2017/048720A1
Disclosed herein are pharmaceutical compositions comprising fencamfamine or fencamfamine related prodrug derivatives for targeted therapeutic applications and methods of synthesizing the compositions.  
WO/2017/042274A1
The present invention relates in a first aspect to compounds for use in the treatment of leukodystrophy whereby these compounds are quinoline derivatives, e.g. laquinimod. In a further aspect, the present invention relates to methods for...  
WO/2017/044551A1
Provided herein are methods for increasing PPARalpha activity and methods for treating PPARalpha related diseases (e.g., mitochondrial diseases).  
WO/2017/044567A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: (I). The compounds induce FOXO1 transcription factor translocation to the nucleus by modulatin...  
WO/2017/044693A1
A combination of a muscarinic cholinergic receptor agonist with a non-anticholinergic antiemetic agent, and the optional addition of an acetyl choline esterase inhibitor, for the treatment of hypocholinergic disorder of the central nervo...  
WO/2017/044491A1
This application relates to methods of treating attention deficit hyperactivity disorder (ADHD), 22q deletion and/or duplication syndrome, and co-morbidities with a nonselective activator of metabotropic glutamate receptors, such as faso...  
WO/2017/044807A3
The invention provides for methods for treating Alzheimer's Disease in a subject by reducing ER-MAM localized APP-C99.  
WO/2017/042196A3
The present invention relates to agents that prevent or reverse process of stem cell senescence. Further, the invention relates to methods and compositions useful in the prevention and/or treatment of stem senescence.  
WO/2017/044486A1
Provided herein is a method of using threonate to alter cellular physiology, such as neuronal physiology. A method of the present disclosure may include providing to a medium comprising a cell, a threonate-containing compound, or a precu...  
WO/2017/042114A1
The present invention relates to compounds of formula (I); hetaryl is a five membered heteroaryl group, containing 1 to 3 heteroatoms, selected from O, S or N; R1 is hydrogen, halogen, lower alkyl, lower alkoxy, lower alkyl substituted b...  
WO/2017/044714A1
A combination of a muscarinic cholinergic receptor agonist, a non-anticholinergic antiemetic agent and a non-selective, peripheral anticholinergic agent for the treatment of hypocholinergic disorders of the central nervous system.  
WO/2017/041180A1
Compounds having the Formula (I), and enantiomers, diastereomers, pharmaceutically acceptable salts, solvates and solvates of salts thereof, (Formula I)) are useful as kinase inhibitors or modulators, including BTK modulation or inhibiti...  
WO/2017/042314A1
The present invention relates to methods and pharmaceutical composition for the treatment of post-traumatic epilepsies. In particular, the present invention relates to a method of treating post-traumatic epilepsy (PTE) in a subject in ne...  
WO/2017/042267A1
The present invention relates to the use of compounds for the prevention and treatment of diseases whose initiation and/or evolution relates to the production and effects of reactive oxygen species (ROS) of mitochondrial origin.  
WO/2017/043494A1
The purpose of the present invention is to provide a microcapsule, said microcapsule containing a biodegradable polymer and risperidone and having excellent sustained release properties, and a method for manufacturing the same. A microca...  
WO/2017/044571A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus : The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP...  
WO/2017/044497A1
Methods and uses for diagnosing and treating Tourette syndrome are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein t...  
WO/2017/044516A1
The present disclosure relates to prodrugs of 7-chlorokynurenic acid. In certain embodiments, the prodrugs include those having the structure of any one of formula (I)-(VIII), wherein R1-R13, monomer 1, monomer 2, and linker are defined ...  
WO/2017/043636A1
To provide a therapeutic agent for diseases associated with Nav 1.7, specifically diseases such as neuropathic pain, nociceptive pain, inflammatory pain, small fiber neuropathy, erythromelalgia, paroxysmal extreme pain disorder, urinatio...  
WO/2017/044503A1
Methods and uses for diagnosing and treating anxiety disorders are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein t...  
WO/2017/041733A1
Provided is a polypeptide that inhibits Aβ protein aggregation of Alzheimer's disease, and an amino acid sequence thereof is Xaa1-Xaa2-Xaa3-Xaa4. Xaa1 and Xaa3 are identical amino acids and selected from I, V or L, Xaa2 is selected from...  
WO/2017/044575A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2...  
WO/2017/041711A1
The invention relates novel pharmaceutical use of kaurane compounds of formula (I) in treating and preventing cardiac hypertrophy and myocardium remodeling. The said compounds also can significantly ameliorate pulmonary hypertension and ...  
WO/2017/044002A1
The invention relates to the chemical and pharmaceutical industry and concerns the use of polyprenols of formula (1) to produce a drug, as well as the drug itself and a pharmaceutical composition containing compound (1) for the treatment...  
WO/2017/044502A1
Methods for diagnosing and treating conduct disorder are encompassed, wherein diagnosis and treatment may be based upon an assessment of genetic alterations in metabotropic glutamate receptor (mGluR) network genes and wherein treatment i...  
WO/2017/041680A1
Provided are a pharmaceutical composition of an amorphous vortioxetine or a salt thereof, and a preparation method therefor. The pharmaceutical composition comprises an amorphous vortioxetine or a pharmaceutically acceptable salt thereof...  
WO/2017/043092A1
The present invention relates to imidazolinone derivatives of the formula (I) or a pharmaceutically acceptable salt thereof or a prodrug thereof, processes for their preparation, pharmaceutical compositions containing them and their use ...  
WO/2017/042643A1
The present invention relates to compound of formula (I), or stereoisomers and pharmaceutically acceptable salts as muscarinic M1 receptor positive allosteric modulators. This invention also relates to methods of making such compounds an...  
WO/2017/042567A1
This invention relates to the use of CBD to treat mental disorders. For example it can be used as an adjunct therapy to treat positive symptoms in mental disorders such as schizophrenia and related disorders; or as an adjunct therapy in ...  
WO/2017/044569A1
A genus of arylsulfonamide derivatives of heterocyclic constrained tricyclic compounds is disclosed. The compounds are of the following genus: The compounds induce FOXO1 transcription factor translocation to the nucleus by modulating PP2...  
WO/2017/037166A1
The present invention relates to 1 -(4-(2-((1 -(3,4-difluorophenyl)-1 H-pyrazol-3-yl)methoxy)ethyl)piperazin-1 -yl)ethanone salts, specifically to the hydrochloride and to the maleate, to pharmaceutical compositions comprising them, and ...  
WO/2017/041037A1
The present invention relates to methods of treating neurodegenerative disorders associated with Alzheimer's disease (AD), Parkinson's disease (PD) and synucleinopathies, such as dementia with Lewy bodies, Down Syndrome (DS) and associat...  
WO/2017/038860A1
The present invention is: a free polyunsaturated fatty acid-containing composition, which comprises at least one C20 or higher free polyunsaturated fatty acid, the content being at least 80.0% of the fatty acids in the composition, and s...  
WO/2017/037812A1
The purpose of the present invention is to provide a patch preparation which uses a basic drug acid addition salt as a raw material and which has excellent skin permeability of the drug. This patch preparation is formed by providing an a...  
WO/2017/036397A1
Provided is a spray of ganoderma lucidum spore extract having undergone supercritical CO2 extraction.  
WO/2017/038925A1
The present invention addresses the problem of providing a pharmaceutical composition that has a high safety and with which the long-term stability can be ensured and the reduction in the amount of an active ingredient accompanying the o...  
WO/2017/037089A1
Compositions and methods use Bifidobacterium longum NCC3001 (ATCC BAA-999) to treat or prevent a depressive symptom. Prolonged anti-depressive effects can continue after administration of the compositions is ended. Non-limiting examples ...  
WO/2017/039525A1
The invention relates to a method of treating a dopamine related disorder in a subject, the method comprises the steps of administering therapy to a subject, the therapy comprising a plurality of doses of levodopa over a selected time pe...  

Matches 301 - 350 out of 122,159